Výsledky vyhledávání - "Jéremy Lupu"

Table S2 from A PD-1/PD-L1 Proximity Assay as a Theranostic Marker for PD-1 Blockade in Patients with Metastatic Melanoma

Autor: Caroline Robert, Stéphan Vagner, Jean-Yves Scoazec, Pascale Morel, SuFey Ong, Kristina Sorg, Sarah Warren, Jéremy Lupu, Emilie Routier, Sara Faouzi, Caroline Brard, Séverine Roy, Shensi Shen, Julien Adam, Isabelle Girault

Results of PLA, CD8 and PDL1 (MELscore) in all the samples

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3aa5d3e7b4d771f42fe8667c88c0ea8d
https://doi.org/10.1158/1078-0432.22482161.v1

Zobrazit plný text záznamu

Data from A PD-1/PD-L1 Proximity Assay as a Theranostic Marker for PD-1 Blockade in Patients with Metastatic Melanoma

Purpose:Less than 50% of patients with melanoma respond to anti–programmed cell death protein 1 (anti–PD-1), and this treatment can induce severe toxicity. Predictive markers are thus needed to improve the benefit/risk ratio of immune checkpoint

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::130342ef5b960dbb0ebd0956b86de8bf
https://doi.org/10.1158/1078-0432.c.6530840

Zobrazit plný text záznamu

Supplementary Figure Legends from A PD-1/PD-L1 Proximity Assay as a Theranostic Marker for PD-1 Blockade in Patients with Metastatic Melanoma

Supplementary Figure Legends

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d847eb45cb025e855425a9ce83ec5e1d
https://doi.org/10.1158/1078-0432.22482167

Zobrazit plný text záznamu

Figure S3 from A PD-1/PD-L1 Proximity Assay as a Theranostic Marker for PD-1 Blockade in Patients with Metastatic Melanoma

Kaplan Meier representation of the progression-free survival (PFS) and overall survival (OS) for PDL1, CD8, TIS and Melscore variables in all samples (exploratory and validation cohorts) with a recapitulive table of survival medians (NA : Not Availab

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0eccd81f44e2537fc5aa6d59e7ceb6dd
https://doi.org/10.1158/1078-0432.22482170.v1

Zobrazit plný text záznamu

Akademický článek

Correction: Combination checkpoint blockade for metastatic cutaneous malignancies in kidney transplant recipients

Publikováno v: Journal for ImmunoTherapy of Cancer, Vol 9, Iss 1 (2021)

Externí odkaz: https://doaj.org/article/a11788d6e7784eafb0cbc66b79d31b22

Zobrazit plný text záznamu

Akademický článek

Clinical impact of COVID-19 on patients with cancer treated with immune checkpoint inhibition

Autor: Dirk Schadendorf, Carola Berking, Lisa Zimmer, Serigne Lo, Caroline Robert, John Haanen, Ines Pires da Silva, Paolo Antonio Ascierto, Reinhard Dummer, Michael Manos, Joanna Mangana, Marcus O Butler, Richard D Carvajal, Georgina V Long, Alon Vaisman, Christian Posch, F Stephen Hodi, Paola Queirolo, Axel Hauschild, Christian U Blank, Maria Grazia Vitale, Carlo Alberto Tondini, Leyre Zubiri, Arielle Elkrief, Karijn P M Suijkerbuijk, Mario Mandala, Alexander M Menzies, Aljosja Rogiers, Chiara Tentori, Joseph M Grimes, Megan H Trager, Sharon Nahm, Peter Bowling, Neha Papneja, April A N Rose, Jessica S W Borgers, Severine Roy, Thiago Pimentel Muniz, Tim Cooksley, Jeremy Lupu, Samuel D Saibil, Matteo S Carlino, Michael Erdmann, Laura Pala, Ryan J Sullivan, Wilson H Miller Jr, Kerry L Reynolds, Osama E Rahma, Paul C Lorigan

Publikováno v: Journal for ImmunoTherapy of Cancer, Vol 9, Iss 1 (2021)

Background Patients with cancer who are infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are more likely to develop severe illness and die compared with those without cancer. The impact of immune checkpoint inhibition (ICI)

Externí odkaz: https://doaj.org/article/0880e80bb8394806afbc90b0e9140059

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání